Relationship between Insulin Resistance and Low Urinary pH in Patients with Gout, and Effects of PPARα Agonists on Urine pH

Abstract

Patients with gout frequently have low urinary pH, though the underlying mechanism has not been identified. Recently, nephrolithiasis has been reported to be involved with renal manifestation of metabolic syndrome. The present study was conducted to clarify the mechanism of low urinary pH in gout patients. The relationships between urine pH and factors contributing to metabolic syndrome were investigated. In addition, the effects of PPARα agonists on urine pH were examined. Patients with 24-hour urine samples below a level of pH 5.5 showed higher values for factors constituting metabolic syndrome, compared with those with 24-hour urine pH equal to or greater than 5.5. Multiple regression analysis demonstrated that HOMA index was the only contributing factor to low urinary pH in gout patients, except for serum uric acid. Administrations of PPARα agonists significantly raised 24-hour urine pH levels in gout patients in accordance with a reduction in serum triglyceride concentration, probably through their activities to improve insulin resistance. Our results suggest that insulin resistance plays an important role in the development of low urinary pH in patients with gout and that PPARα agonist is preferable for raising urinary pH of the gout patients with hypertriglyceridemia.

Key words

Acidic urine - hyperuricemia - insulin - HOMA-R - fenofibrate - bezafibrate

References

• 1 Scott E. Epidemiology of stone disease.  Br J Urol. 1985;  57 491-497
• 2 Yu TF, Gutman AB. Uric acid nephrolithiasis in gout.  Ann Intern Med. 1967;  67 1133-1148
• 3 Pak Poy RK. Urinary pH in gout.  Australas Ann Med. 1965;  14 35-39
• 4 Alvarez-Nemegyei J, Medina-Escobedo M, Villanueva-Jorge S, Vazquez-Mellado J. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed?.  J Rheumatol. 2005;  32 2189-2191
• 5 Abate N, Chandalia M, Cabo-Chan Jr AV, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestations of insulin resistance.  Kidney Int. 2004;  65 386-392
• 6 Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.  Int J Clin Pharmacol Ther. 2004;  42 212-217
• 7 Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity.  J Biol Chem. 2000;  275 16638-16642
• 8 Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.  Biochem Biophys Res Commun. 2002;  296 293-299
• 9 Wallace SL, Robinson H, Masi AT, Decker JL, MacCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout.  Arthritis Rheum. 1977;  20 895-900
• 10 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 11 Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.  Ann Rheum Dis. 2003;  62 572-575
• 12 Gutman AB, Yu TF. Urinary ammonium excretion in primary gout.  J Clin Invest. 1965;  44 1474-1481
• 13 Falls Jr WF. Comparison of urinary acidification and ammonium excretion in normal and gouty subjects.  Metabolism. 1972;  21 433-445
• 14 Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout - influence of alcohol intake and body weight.  Br J Rheumatol. 1994;  33 731-734
• 15 Klisic J, Hu MC, Nief V, Reyes L, Fuster D, Moe OW, Ambuhl PM. Insulin activates Na⁺/H⁺ exchanger 3 (NHE3): biphasic response and glucocorticoid dependence.  Am J Physiol Renal Physiol. 2002;  283 F532-F539
• 16 Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism.  J Clin Endocrinol Metab. 1988;  66 140-146
• 17 Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner AH, Kann P, Forst T. Pioneer study: PPARγ activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.  Horm Metab Res. 2005;  37 510-515
• 18 Forst T, Hohberg C, Fuellert SD, Lübben G, Konrad T, Löbig M, Weber MM, Sachara C, Gottschall V, Pfützner A. Pharmacological PPARγ stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes.  Horm Metab Res. 2005;  37 521-527

Correspondence